Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving HealthEquity, Inc and its officers or directors [1] Financial Performance - On March 18, 2025, HealthEquity reported its financial results for the fourth quarter and fiscal year ending January 31, 2025, with earnings per share that fell short of analyst expectations [3] - The company provided weak guidance for the fiscal year ending January 31, 2026, indicating potential challenges ahead [3] Stock Market Reaction - Following the announcement of disappointing earnings and guidance, HealthEquity's stock price dropped by $17.35 per share, or 17.07%, closing at $84.32 per share on March 19, 2025 [3] Cybersecurity Concerns - HealthEquity's management cited "excess service expense" due to increased cyber threats and fraud attacks, which have been attributed to sophisticated techniques employed by malicious actors [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Watsco, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Watsco reported first-quarter 2025 revenue of $1.53 billion, which is a 2% decline year-over-year and below consensus estimates [3]. - The company indicated that the results are influenced by a large-scale product transition due to regulatory changes effective January 1, 2025, impacting approximately 55% of its sales and expected to convert nearly $1 billion of inventory throughout the year [3]. - Following the announcement, Watsco's stock price decreased by $56.76 per share, or 11.28%, closing at $446.40 per share on April 23, 2025 [3].

Core Viewpoint - Landstar System, Inc. is under investigation for potential securities fraud and unlawful business practices following the disclosure of significant supply chain fraud that may impact its earnings [1][3]. Financial Impact - On April 2, 2025, Landstar announced that the identified fraud could adversely affect its first quarter 2025 earnings per share by $0.35 to $0.50, leading to a stock price drop of $13.30, or 8.75%, closing at $138.63 on April 3, 2025 [3]. - On April 25, 2025, Landstar revealed it would be unable to file its quarterly report on time due to ongoing evaluations related to the fraud, resulting in a further stock price decline of $4.92, or 3.52%, closing at $135.00 [4]. Legal Proceedings - Pomerantz LLP is investigating claims on behalf of Landstar investors, indicating potential class action litigation related to the alleged fraud [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. and its officers or directors [1] Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3] - Following this announcement, Senti's stock price dropped by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share on the same day [3] Group 2: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Senti Biosciences, indicating a potential class action lawsuit [1][2] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Wabash National Corporation and its officers or directors [1] Financial Performance - Wabash reported an operating loss of $9.8 million in its Transportation Solutions segment for Q1 2025, a significant decline from an operating profit of $44.25 million in Q1 2024 [3] - The gross profit for Wabash in Q1 2025 was only $19 million, compared to $76.4 million in Q1 2024 [3] - The company revised its annual revenue forecast to approximately $1.8 billion, down from the previous projection of $1.9 billion issued in February 2025 [3] Market Reaction - Following the announcement of its financial results, Wabash's stock price fell by $3.05 per share, or 30.62%, closing at $6.91 per share on April 30, 2025 [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - The U.S. Department of Justice filed a False Claims Act complaint against GoHealth and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [3] - Following the DOJ's lawsuit announcement, GoHealth's stock price dropped by $1.09 per share, a decrease of 10.35%, closing at $9.44 per share on May 1, 2025 [3]

If you purchased or acquired Treace Medical securities, and/or would like to discuss your legal rights and options please visit Treace Medical Concepts, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com. According to the Complaint, Defendants made misrepresentations concerning the impact of competition on demand for, and utilization of, the Company's primary product, the Lapiplasty 3D Bunion Correction System. If you wish to ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Group 1: Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]

Group 1 - A class action lawsuit has been filed against Napco Security Technologies, Inc. for alleged securities fraud and unlawful business practices [2][4]. - Investors have until June 24, 2025, to request appointment as Lead Plaintiff if they purchased Napco securities during the Class Period [2]. - Napco reported a significant decline in hardware sales attributed to reduced sales from two major distributors, leading to the withdrawal of its long-term 45% EBITDA margin target [4]. Group 2 - Following the announcement of the financial results, Napco's stock price dropped by $9.77 per share, or 26.62%, closing at $26.93 per share on February 3, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against ICON Public Limited Company for alleged violations of securities laws, claiming the company made false and misleading statements that led to investor losses [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between July 27, 2023, and October 23, 2024, during which investors are encouraged to contact the Schall Law Firm for participation [2]. - The complaint alleges that ICON's misleading statements were related to its business performance and customer engagements, which were negatively impacted by funding limitations faced by its customer base [4]. Group 2: Company Performance Issues - ICON's Functional Service Provision (FSP) and hybrid models did not safeguard the company from market downturns, leading to contract cancellations and reduced engagements from clients [4]. - The two largest clients of ICON began diversifying their contract research organization (CRO) providers, which further contributed to the company's declining business [4].